This new volume delves into the extensive new research on inflammatory bowel disease (IBD) and gut microbiota that has led to effective therapeutic interventions. Highlighting novel methodologies and innovative treatment approaches, the book provides a comprehensive investigation of IBD, exploring the significance of gut microbiota and investigating the fundamental role of microbial imbalances in the initiation and progression of inflammatory processes as well as the prominent therapeutic consequences of restoring microbial homeostasis. From nanoparticle-based drug delivery systems that advance the bioavailability of the medicament to the use of bio-nanosensors for early detection of disease, the book covers a broad spectrum of inventions that hold potential for revolutionizing IBD treatment. The authors look at the impact of nutraceuticals, probiotics, prebiotics, functional foods, oral siRNA-based nanomedicine, and other novel drug delivery systems on gut microbiota for the management of IBD. The book also explores the role of reactive oxygen species (ROSs), superoxide dismutases (SODs), and inflammation in association with gut microbiota and IBD.